PMV Pharmaceuticals, Inc. (NASDAQ:PMVP – Get Free Report) insider Deepika Jalota sold 4,104 shares of the company’s stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $6.62, for a total transaction of $27,168.48. Following the transaction, the insider now owns 29,946 shares in the company, valued at approximately $198,242.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
PMV Pharmaceuticals Price Performance
PMVP stock traded down $0.50 during mid-day trading on Monday, reaching $6.21. 265,103 shares of the company’s stock were exchanged, compared to its average volume of 488,016. The company has a market cap of $300.94 million, a price-to-earnings ratio of -3.87 and a beta of 0.93. PMV Pharmaceuticals, Inc. has a 12-month low of $3.84 and a 12-month high of $13.02. The stock’s 50 day moving average is $7.02 and its 200 day moving average is $5.94.
PMV Pharmaceuticals (NASDAQ:PMVP – Get Free Report) last released its earnings results on Wednesday, August 9th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.09. On average, research analysts forecast that PMV Pharmaceuticals, Inc. will post -1.67 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Hedge Funds Weigh In On PMV Pharmaceuticals
Hedge funds have recently made changes to their positions in the company. Swiss National Bank grew its holdings in shares of PMV Pharmaceuticals by 8.5% during the first quarter. Swiss National Bank now owns 26,800 shares of the company’s stock worth $558,000 after buying an additional 2,100 shares in the last quarter. US Bancorp DE grew its stake in PMV Pharmaceuticals by 2,588.0% during the 1st quarter. US Bancorp DE now owns 2,016 shares of the company’s stock valued at $42,000 after acquiring an additional 1,941 shares in the last quarter. MetLife Investment Management LLC raised its holdings in PMV Pharmaceuticals by 58.5% in the 1st quarter. MetLife Investment Management LLC now owns 16,818 shares of the company’s stock valued at $350,000 after acquiring an additional 6,207 shares during the last quarter. Rhumbline Advisers lifted its stake in PMV Pharmaceuticals by 7.7% in the 1st quarter. Rhumbline Advisers now owns 27,690 shares of the company’s stock worth $577,000 after purchasing an additional 1,983 shares in the last quarter. Finally, BlackRock Inc. grew its position in shares of PMV Pharmaceuticals by 4.0% in the first quarter. BlackRock Inc. now owns 2,640,350 shares of the company’s stock valued at $54,970,000 after purchasing an additional 100,526 shares in the last quarter.
About PMV Pharmaceuticals
PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.
- Five stocks we like better than PMV Pharmaceuticals
- Dividend Payout Ratio Calculator
- 2 Recession-Proof Intelligence Stocks to Defend Your Portfolio
- What Investors Need to Know to Beat the Market
- 5 Reasons Mullen Automotive is About to Turn a Corner
- The How And Why of Investing in Oil Stocks
- Qualcomm and Apple Forge Ahead with New Modem Partnership
Receive News & Ratings for PMV Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PMV Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.